

# 1 Continuity of services for patients with tuberculosis in China in the COVID-19 era

2 Xin Shen,\* Wei Sha,\* Chongguang Yang,\* Qichao Pan, Ted Cohen, Shiming Cheng, Qingshan Cai,  
3 Xiaohong Kan, Peilan Zong, Zhong Zeng, Shouyong Tan, Ruixia Liang, Liqiong Bai, Jia'an Xia,  
4 Shucai Wu, Peng Sun, Guihui Wu, Cui Cai, Xiaolin Wang, Kaixing Ai, Jianjun Liu, Zheng'an Yuan

## 6 Affiliations:

7 Division of TB and HIV/AIDS Prevention, Shanghai Municipal Center for Disease Control and  
8 Prevention, Shanghai, China (X Shen, PhD); Department of Tuberculosis, Shanghai Pulmonary  
9 Hospital, Shanghai, China (W Sha, PhD); Department of Epidemiology of Microbial Diseases, Yale  
10 School of Public Health, Yale University, New Haven, CT, USA (C Yang, PhD; Professor T Cohen,  
11 DPH, MD, MPH); Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China  
12 (Professor Q Pan, MD; Professor Z Yuan, MD); Shanghai Pulmonary Hospital, Shanghai, China  
13 (Professor K Ai, MD); Chinese Center for Diseases Control and Prevention, Beijing, China (Professor  
14 J Liu, MD); China Anti-tuberculosis Association, Beijing, China (Professor S Chen, MD); Division of  
15 Tuberculosis, Zhejiang Provincial Integrated Chinese and Western Medicine Hospital, Hangzhou,  
16 Zhejiang Province, China (Q Cai, MD); Department of Scientific Research and Education, Anhui  
17 Chest Hospital, Hefei, Anhui Province, China (X Kan, MD, MPH); Division of Tuberculosis, Jiangxi  
18 Chest Hospital, Nanchang, Jiangxi Province, China (P Zong, MD); Division of Tuberculosis, The  
19 Fifth People's Hospital, Ganzhou, Jiangxi Province, China (Z Zeng, MD); Department of  
20 Tuberculosis, Guangzhou Chest Hospital. Guangzhou, Guangdong Province, China (Professor S Tan,  
21 MD); Department of Tuberculosis, Henan Provincial Chest Hospital, Zhengzhou, Henan Province,  
22 China (R Liang, MD); Hunan Chest Hospital, Changsha, Hunan Province, China (Professor L Bai,  
23 MD, PhD); South Five Disease Zones, Wuhan Jinyintan Hospital, Wuhan, Hubei Province, China (J  
24 Xia, MD); Hebei Province Chest Hospital, Shijiazhuang, Hebei Province, China (S Wu, MD);  
25 Tuberculosis Hospital of JiLin Province, Changchun, Jilin Province, China (P Sun, MD); Department  
26 of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, Sichuan Province, China (G  
27 Wu, MD); Tuberculosis Diagnosis and Treatment Quality Control Center, Guiyang Public Health  
28 Treatment Center, Zunyi Medical University, Zunyi, Guizhou Province, China (C Cai, MD); The  
29 Fourth People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia Hui Autonomous  
30 Region, China (X Wang, MD).

31

32

33 **Key words:** Tuberculosis, COVID-19, medical service, public health policy.

34 **Word count:** 2,790

35

36 \* These authors contributed equally to this work.

37 Correspondence to: Prof. Kaixing AI, email: [kaixin\\_ai@163.com](mailto:kaixin_ai@163.com), Shanghai Pulmonary Hospital,  
38 Shanghai 200433, China, Telephone:+86-21-65115006 ;or Prof. Jianjun Liu, China Center for  
39 Diseases Control and Prevention, Beijing 102206, China, email: [jjliu@chinacdc.gov](mailto:jjliu@chinacdc.gov), Telephone: +86-  
40 10-58900001; or Prof. Zheng'an Yuan, Shanghai Municipal Center for Disease Control and  
41 Prevention, Shanghai 200336, China, Email: [yuanzhengan@scdc.sh.cn](mailto:yuanzhengan@scdc.sh.cn), Telephone: +86-21-  
42 62758710

43

44 **Running title:** Continuity of TB services in China in the COVID-19 era

45

46

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 **Abstract (173 words)**

48 It is crucial to maintain continuity of essential services for people affected by tuberculosis (TB).  
49 Efforts to deliver these essential services in many global settings have been complicated by the  
50 emergence and global spread of SARS-CoV-2 and the pandemic of COVID-19. Understanding how  
51 the COVID-19 pandemic has impacted the availability of TB diagnostic and treatment services is  
52 critical for identifying policies that can mitigate disruptions of these essential services. China has a  
53 dual burden of TB and COVID-19. We conducted a survey and collected data from 13 provinces in  
54 China to evaluate the early impact of COVID-19 on TB services and to document interventions that  
55 were adopted to maintain the continuity services for TB patients during the pandemic. We use these  
56 data to identify additional opportunities which will improve the ability of TB programs to maintain  
57 essential services during this crisis. While health systems and underlying epidemiology differ between  
58 countries, we believe that sharing China's experience can inform the design of locally tailored  
59 strategies to maintain essential TB services during the COVID-19 pandemic.

## 60 **Introduction**

61 The emergence and spread of the novel coronavirus SARS-CoV-2 has caused a pandemic of COVID-  
62 19<sup>1</sup>. The COVID-19 pandemic poses unprecedented challenges for health systems. In addition to  
63 imposing new demands of these systems to respond to this novel virus, the rapid spread of SARS-  
64 CoV2 threatens access to and delivery of essential health services that were needed prior to the  
65 pandemic<sup>2</sup>.

66 Tuberculosis (TB) is the leading infectious cause of death due to a single pathogen. TB diagnosis  
67 depends on individuals with symptoms having access to diagnostic facilities, and TB treatment  
68 requires daily adherence to antibiotic treatment, often directly observed by healthcare personnel, for  
69 six months or longer. TB diagnosis and care is thus a major public health undertaking, and while  
70 investment in TB control is one of the single most cost-effective health interventions, TB programs  
71 are often operating with limited budgets. Many leading international agencies and organizations  
72 coordinating global efforts for TB control, including WHO and STOP-TB Partnership, have voiced  
73 concern about the potential of COVID-19 to undermine recent gains in TB control.

74 New data validate concerns about the detrimental impact of COVID-19 on the operational capacity of  
75 TB control programs. A recent modelling study estimated an additional 190, 000 TB deaths (a 13%  
76 increase) in 2020 if global TB case detection decreases by an average 25% over a period of three  
77 months (as compared to the level of detection before the pandemic), bringing us back to the levels of  
78 TB mortality that we had five years ago<sup>3</sup>. Currently, it is urgent to maintain continuity of essential  
79 services for people affected by TB during the COVID-19 pandemic.

80 China faces the dual burden of COVID-19 and TB since first outbreak of COVID-19 in Wuhan in  
81 December 2019<sup>4,5</sup>. As COVID-19 emerged in Wuhan, China used aggressive public health  
82 interventions to mitigate spread including lockdown of cities, and restriction of public transportation.  
83 In addition, there was substantial re-allocation of existing medical resources to meet the needs of the  
84 COVID-19 patients. These shifts included the temporary re-designation TB hospitals as special  
85 COVID-19 hospitals. Though these measures have thus far succeeded in limiting the local spread and  
86 health effects of COVID-19<sup>6</sup>, there are concerns that these efforts may have negative consequences  
87 for TB control and care of existing TB patients.

88 Here we developed a hospital-based survey to better characterize the impact of COVID-19 on TB care  
89 in China. We also describe how personnel at TB hospitals and TB programs have developed creative  
90 strategies to maintain continuity of care for TB patients during the COVID-19 pandemic. We compare  
91 specific metrics of TB diagnosis and treatment during three phases: pre-pandemic phase (2019), the  
92 emergency response phase (January to March 2020), and the mitigation phase (April 2020). We also  
93 describe anticipated recommendations for next steps. Given the global nature of the COVID-19 crisis,  
94 we believe that sharing China's experience can help other TB programmes minimize disruptions in  
95 TB care and TB control during the ongoing struggle against COVID-19.

## 96 **Survey Design**

97 The National and Shanghai Anti-tuberculosis Associations organized this survey and invited the  
98 representative TB-designated hospitals in provinces which were affected mostly by COVID-19 in  
99 China. Overall, thirteen invited TB hospitals from thirteen provinces in different part of the mainland  
100 China (including the most affected Wuhan city in Hubei province, Figure 1) participated this  
101 questionnaire survey. Each of the included TB hospitals established special hospital-wide crisis teams  
102 to evaluate local trends of COVID-19 as well as other diseases, including TB, and centrally  
103 coordinate their response to prevent conflicting department-specific strategies. These 13 provinces  
104 reported over 50% (414,673) of newly diagnosed pulmonary TB cases in 2018, and reported 91.8%  
105 (76,088) of COVID-19 cases until April 30, 2020 in China. Each TB hospital enrolled in this study  
106 was within the top three hospitals in terms of province-wide numbers of pulmonary TB in 2018-2019.  
107 Although the sample size of the survey is limited, it covers all seven regions in mainland China

108 (Figure 1), and thus the survey results represent the status of tuberculosis diagnosis and treatment  
109 services at the provincial level tuberculosis designated hospitals during the COVID-19 outbreak.

110 In this survey, we divided COVID-19 epidemics in China in three periods: the pre-pandemic phase  
111 (2019), the outbreak emergency response phase (January through March, 2020); and the outbreak  
112 mitigation phase (April, 2020). We conducted a pilot study in one hospital prior the full scale-up of  
113 the survey. We collected information about three aspects of TB diagnosis and care during the  
114 outbreak: 1) Changes in hospital-based diagnosis of TB patients; 2) Changes in the availability of  
115 hospital-based TB services; and 3) Adjustment of hospital-based TB services.

## 116 Findings

117 **Changes in the detection of TB.** Compared with the same period of 2019, the number of TB patients  
118 diagnosed significantly decreased during the pandemic (Table 1). In the emergency response phase,  
119 eleven hospitals reported a median decrease of 25% in the number of TB patients detected. Two  
120 hospitals reported small increases in TB diagnoses. In the mitigation phase, ten hospitals had smaller  
121 numbers of TB diagnoses compared to April 2019; however, the gap was decreased (median  
122 reduction of 15%) compared with the decreases observed in the emergency response phase.

123 **Changes in the availability of hospital-based TB services.** In the emergency response phase, nine  
124 of the 13 hospitals in our study had been designated as COVID-19 hospitals and shifted at least some  
125 fraction of designated (median 75.7%, range, 21.1-100.0%) TB beds for COVID-19 care. Four of the  
126 hospitals converted 100% of TB beds to COVID-19 beds during this period. Twelve of the 13 TB  
127 hospitals dispatched professional TB staff for COVID-19 service (28.5%, 3.0-100.0%). Among the  
128 nine hospitals that continued inpatient services for TB, five (38.5%) set stricter indications for TB  
129 hospitalization than had previously been used. For example, only those patients with severe  
130 tuberculosis, such as patients with hemoptysis, with massive pleural effusion, or those with drug-  
131 resistant TB, would be admitted to the hospital. Ten (77.0%) of 13 hospitals set restrictions for the  
132 numbers of outpatient visits. These measures significantly decreased the supply of TB services.  
133 Compared with the same period in the previous year (January-March 2019), there were 34% (6-99%)  
134 and 30% (11-100%) reductions in the number of outpatient visits and the number of admissions in the  
135 emergency response phase, respectively (Table 1).

136 In the mitigation phase, the fraction of TB medical resources deployed for COVID-19 gradually  
137 decreased. Five hospitals still shifted the TB beds for COVID-19 but with a decreased median  
138 proportion of 43.6% (5.0-53.3%) compared to emergency response phase. Twelve TB hospitals  
139 continue to dispatch professional TB staff for COVID-19, but the proportion of TB staff repurposed  
140 for decreased from 28% to 10% (Table 1). The number of hospitals that set stricter indications for  
141 hospitalization or set a restriction for maximum outpatient visits both decreased to three (23.1%).  
142 Compared with the same period of April 2019, the decline has narrowed for the number of outpatient  
143 visits, the number of patients' admission and discharge for each TB hospitals (Table 1), indicating the  
144 gradually restoration of TB medical services. One notable exception is the Jinyintan Hospital in the  
145 Wuhan -- the city at the epicenter of this outbreak<sup>7</sup> -- where the number outpatient visits and inpatient  
146 admissions of TB cases was severely reduced (>90%) throughout all COVID-19 outbreak phases.

147 **Adjustment of hospital-based TB services.** In order to maintain continuity of essential services for  
148 people affected by TB during the COVID-19 pandemic, TB hospitals in China made a number of  
149 modifications to existing hospital-based TB services. These include changes in treatment monitoring  
150 and hospitalization policies, changes to approaches for TB patient support, and changes to infection  
151 prevention and control (Table 2).

152 **1. Anti-TB treatment.** Across the 13 TB hospitals, anti-TB treatment regimens have been adapted for  
153 two main reasons: (1) to minimize the number of hospital visits and hospitalizations, and (2) to ensure  
154 the continuity of anti-TB treatment. There were five strategies reported by the TB hospitals. First,  
155 most hospitals have set stricter indications of hospitalization, as mentioned above. Second,  
156 distribution of longer-term prescriptions have been widely used to ensure that TB patients would have  
157 sufficient medications for TB treatment. Nine hospitals provided 2-3 months medications, and four

158 hospitals provided 1-month medications for TB patients during the emergency phase, compared to 1-2  
159 week medications prior this pandemic. Third, most hospitals (11 of 13) converted injectable  
160 treatments to all oral regimens for patients with multidrug-resistant TB (MDR-TB) to reduce the  
161 frequency patient's visits to hospitals to avoid COVID-19 infection. Fourth, all of the hospitals used  
162 digital medical technologies such as instant messaging, and/or telephone calls to follow-up TB  
163 patients. Fifth, 11 of 13 hospitals provided drug delivery services for TB patients who started  
164 treatment but who were not easily able to visit the hospital to receive medication.

165 **2. Patient support.** In our survey, all the hospitals reported that TB patients were often willing to  
166 accept suggested preventive measures to avoid infection. Meanwhile, all of 13 hospitals reported that  
167 there was increased anxiety among patients with TB compared to the pre-COVID period. The demand  
168 for counseling and mental-health assistance is skyrocketing. Questions that patients ask frequently  
169 have been typically focused on: 1) the possibility of co-infection with *Mycobacterium tuberculosis*  
170 (*M. tb*) and SARS-Cov-2; 2) how to prevent COVID-19 during clinic/hospital visit, and 3) the impact  
171 of COVID-19 on TB treatment and hospital visits.

172 To address patients' concerns, TB hospitals have strengthened patient support by adopting multiple  
173 interventions. All hospitals had patient-friendly web-based educational material for both TB and  
174 COVID-19 and developed and disseminated paper educational materials on both TB and COVID-19.  
175 Seven hospitals used instant messaging, short message service and/or telephone to follow up patients  
176 and provide consultation. One hospital developed a mobile application for providing personal  
177 consultation. Considering the limited in-person interactions with health care workers, and increasing  
178 patients' anxiety caused by COVID-19, patient support appears vitally important to ensure continuity  
179 of TB care in the midst of this crisis.

180 **3. Infection prevention and control.** The COVID-19 crisis has significantly raised people's  
181 awareness of infection control and personal protection for respiratory infectious diseases<sup>8,9</sup>. All 13 TB  
182 hospitals reported that the COVID-19 pandemic resulted in greater general awareness of the  
183 importance of infection prevention and control for TB. Consistent with WHO guidelines<sup>10</sup>, hospitals  
184 have strengthened the measures on TB infection prevention and control as follows: (1) All TB  
185 patients are screened for COVID-19 through an appropriate triage system. TB patients screening  
186 negative for COVID-19 can be sent directly to TB services, while TB patients screening positive for  
187 COVID-19 are separated within a COVID-19 investigation area. (2) All patients and visitors are  
188 required to wear a surgical mask when at the hospitals. (3) All hospitals have strengthened  
189 environmental disinfection and ventilation system. Both natural and mechanical ventilation systems  
190 are commonly used. (4) Eleven (84.6%) of these 13 TB hospitals use upper-room germicidal  
191 ultraviolet (UGA) system in the consulting room and wards for TB. (5) All of the participating  
192 hospitals reduced the usage of bronchoscopy for TB patients by a median of 67% (24-100%) during  
193 the emergency response phase and by 27.5% (6-90%) in mitigation phase (Table 1).

194 For general clinical activities, there were several additional measures taken by TB hospitals to prevent  
195 transmission. First, all visitors were screened for fever and known exposures to COVID-19. Patients  
196 who had symptoms consistent with COVID-19 were isolated rapidly in all 13 hospitals and received  
197 urgent diagnostic evaluation. Second, remote medical services were widely implemented for TB care.  
198 Eleven TB hospitals provided online appointments to reduce the number of visits and to reduce visit  
199 waiting times. The proportion of online appointment increased from 8% (5-90%) in 2019 to 17% (10-  
200 100%) during the emergency phase and 19% (12-90%) in mitigation phase. Four hospitals provided  
201 online remote diagnosis and treatment services for those who could not visit the hospital. Third, all  
202 TB hospitals set stricter restriction for visitors. For patients admitted to the hospitals, three hospitals  
203 did not allow any visitors and the other ten hospitals allowed only a single visitor per patient. For  
204 patients seeking outpatient care, three hospitals did not allow any visitors to accompany the patient  
205 and nine hospitals allowed only a single visitor, the remaining one did not set any restriction.

## 206 Discussion

207 In this survey, we have gained insight into the impact of the COVID-19 outbreak on the continuity of  
208 hospital-based TB services. Most TB services, including diagnosis inpatient and outpatient care,

209 decreased substantially during the COVID-19 emergency response phase. There were two main  
210 drivers for these changes: (1) TB hospitals were temporarily converted to designated COVID-19  
211 hospitals to handle the expected pandemic surge; (2) TB hospitals reduced the number of  
212 consultations and hospitalizations to reduce the risk of nosocomial transmission of COVID-19.

213 The observed decrease in TB case detection at the surveyed hospitals raises concerns for TB control  
214 efforts. Given the slow secular decline in TB incidence in China<sup>11</sup>, the dramatic decline in TB  
215 diagnoses during the pandemic is almost certainly the result of changes in care seeking and access  
216 attributable to COVID-19. There were clearly documented limitations in available TB services caused  
217 by the response to COVID-19 and other movement restrictions likely led to further barriers for  
218 probable TB patients to access diagnosis and care. Further, although our survey does not document  
219 this phenomenon, it seems likely that concerns about SARS-CoV-2 transmission in health facilities  
220 and on public transportation may have prevented individuals from seeking TB diagnosis or care.

221 The impact of COVID-19 on the health system and the potential for COVID-19 responses to  
222 undermine TB control efforts are already clear. This pandemic presents difficult challenges for  
223 national and local TB programs and suggests a need to understand how to ensure that COVID-19  
224 responses disrupt TB services as little as possible. Based on these hospitals' experiences, we propose  
225 two specific recommendations:

226 *Timely modification of TB services.* To mitigate the impact of COVID-19 on TB care and control,  
227 national and local TB programs should commit to interventions which can maintain the continuity of  
228 essential services for TB patients. For example, provision of adequate stocks of medicines for all TB  
229 patients can ensure treatment completion without unnecessary hospital visits to collect medications.  
230 As China and many other high TB burden countries remain reliant on in-person and community-based  
231 DOTS for TB treatment, modification of current in-person TB services in preference for more  
232 innovative patient-centered approaches may improve patients adhere to their treatment during this  
233 and future crises. Digital-health technologies like instant messaging, electronic medication monitors,  
234 and video-supported therapy<sup>12, 13</sup> can play an important role in this transition. Online diagnosis and  
235 treatment services should be further explored so that patients can have opportunities to access medical  
236 care regardless of distance from clinics.

237 *Integration of services for COVID-19 and TB.* There are striking similarities between the COVID-19  
238 and TB. Both can present with respiratory symptoms such as cough, fever, and difficulty breathing.  
239 Both are transmitted mainly via close contact. The integration of services for COVID-19 and TB can  
240 assist in curbing both epidemics to save lives. Accurate diagnostic tests are essential for both TB and  
241 COVID-19. Though tests for the two conditions are different, both should be made available for  
242 individuals with respiratory symptoms, so both diseases can utilize the capacity building efforts, along  
243 with surveillance and monitoring systems, as well as diagnostic tools such as GeneXpert and chest  
244 radiography. In countries with local transmission of COVID-19, the case-finding strategies are being  
245 modified to an active approach. Although active TB case finding has not been scale-up in many high  
246 TB burden countries, there is a potential for the collaboration between activities of case finding for  
247 both TB and COVID-19, such as close contact screening and tracing, testing of patients with severe  
248 pneumonia that does not respond to antibiotics, which can help to quickly detect patients with both  
249 diseases.

250

## 251 **Conclusions**

252 Our survey reveals a significant disruption of TB diagnosis and care at major hospitals throughout  
253 China as a result of COVID-19. These disruptions were most dramatic at the peak of the epidemic,  
254 and numbers of TB diagnoses and TB inpatient facilities have gradually returned toward normal  
255 levels as COVID-19 incidence receded in April 2020. We also report innovative efforts adopted by  
256 hospitals to maintain the continuity of care TB patients during the pandemic. As many countries with  
257 high TB burden are still attempting to control COVID-19, our experiences in China offer important  
258 lessons for other health systems grappling with maintain TB services in the midst of this crisis. We  
259 believe that patient-centered approaches to TB diagnosis and care, which were already being

260 promoted before the emergence of COVID-19, should have new urgency and motivation. We urgently  
261 call for additional investment directed toward improving the availability of diagnostics and  
262 therapeutics such that equitable access to care can be maintained during times of crisis.

263 **Contributors**

264 XS, KA, JL, and ZY had the idea for this report, with input from WS, CY, QP, and SC. XS and WS  
265 designed the questionnaire. WS, QC, XK, PZ, ZZ, ST, RL, LB, JX, SW, PS, GW, CC, and XW  
266 collected the data. XS and CY reviewed published literatures, analyzed the data, made the tables and  
267 figure, and wrote the first draft. TC, WS, QP, SC, KA, JL, and ZY reviewed and revised the report.  
268 All authors approved the final version.

269 **Declaration of interests**

270 We declare no competing interests.

271 **Acknowledgements**

272 This study received funding from the Chinese National Science and Technology Major Projects (grant  
273 2018ZX10715012 to XS and ZY), and the Natural Science Foundation of China (grant 81872679 to  
274 XS and QP). CY received funding from the Robert E. Leet and Clara Guthrie Patterson Trust  
275 Mentored Research Award. All the funding sources had no role in the preparation of this report.



276 **Figure Legends**

277 Figure 1 Distribution of annual notified tuberculosis patients in 2018 and COVID-19 patients by  
278 April 30, 2020 in the 13 provinces. The size of circle represents the number of tuberculosis (orange)  
279 and COVID-19 cases (blue). The Hubei province was the only one with more accumulated COVID-  
280 19 cases than the annual notified tuberculosis cases.


281 **Tables**

282 Table 1. Impact of COVID-19 on TB services in 13 TB hospitals in China, 2020

283 Table 2. Major changes in caring for patients with tuberculosis in China during the COVID-19  
284 pandemic

285 **References**

- 286 1. World Health Organization. WHO Director-General's opening remarks at the media briefing on  
287 COVID-19. March 11, 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
288 [opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020) (accessed June 6, 2020) .
- 289 2. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of  
290 Covid-19. *N Eng J Med* 2020;382:2049-55
- 291 3. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020.  
292 <https://www.medrxiv.org/content/10.1101/2020.04.28.20079582v1> (accessed June 6, 2020) .
- 293 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with  
294 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054-62.
- 295 5. World Health Organization. Global tuberculosis report 2019.  
296 [https://www.who.int/tb/publications/global\\_report/en/](https://www.who.int/tb/publications/global_report/en/) (accessed June 6, 2020) .
- 297 6. Li Z, Chen Q, Feng L, et al. Active case finding with case management: the key to tackling the  
298 COVID-19 pandemic. *Lancet* 2020; published online June 4, 2020. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(20)31278-2)  
299 [6736\(20\)31278-2](https://doi.org/10.1016/S0140-6736(20)31278-2).
- 300 7. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019  
301 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395(10223): 507-  
302 13.
- 303 8. Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of  
304 COVID-19: a mathematical modelling study. *Lancet Infect Dis* 2020; 20: 553-8.
- 305 9. Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50  
306 days of the COVID-19 epidemic in China. *Science* 2020; 368: 638-42.
- 307 10. World Health Organization. WHO guidelines on tuberculosis infection prevention and control  
308 2019 update. [https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-](https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/)  
309 [2019/en/](https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/) (accessed June 6, 2020) .
- 310 11. Guo C, Du Y, Shen S, et al. Spatiotemporal Analysis of Tuberculosis Incidence and Its Associated  
311 Factors in Mainland China. *Epidemiol Infect* 2017;145:2510-9.
- 312 12. Wang N, Zhang H, Zhou Y, et al. Using electronic medication monitoring to guide differential  
313 management of tuberculosis patients at the community level in China. *BMC Infect Dis* 2019; 19: 844.
- 314 13. Liu X, Lewis JJ, Zhang H, et al. Effectiveness of Electronic Reminders to Improve Medication  
315 Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. *PLoS Med* 2015; 12: e1001876.



**Table 1. Impact of COVID-19 on TB services in 13 TB hospitals in China, 2020**

Category	Pre-pandemic phase	Pandemic phase	Recovery phase
<b>TB medical services</b>			
Change in No. of TB beds*&	100%	Decreased (median -75.7%, range -100% ~ -21%)	Decreased (median -43.6%, range -53.3 ~ -5.0%)
Change in No. of professional TB staff*&	100%	Decreased (median -28.5%, range -100% ~ -3%)	Decreased (median -10%, range -38% ~ 0%)
No. of hospitals set strict indications for hospitalization	0	38.5%	23.1%
No. of hospitals set restriction for maximum outpatient visits	23.1%	30.8%	23.1%
Change in No. of outpatient visits&	100%	Decreased (median -34%, range -99% ~ -6%)	Decreased (median -20%, range -90% ~ -2%)
Change in No. of patients' admission&	100%	Decreased (median -30%, range -100% ~ -11%)	Decreased (median -18%, range -95% ~ 0%)
<b>Detection of TB patients</b>			
Change in No. of TB patients detected &	100%	Decreased (median -25%, range -100 ~ +11%)	Decreased (median -15%, range -90 ~ +15%)

\* TB beds and professional TB staff were deployed for COVID-19.

& Compared with the same period of 2019.

Pre-pandemic phase = the same period of 2019, Emergency phase = January – March 2020, Recovery phase = April 2020, TB = tuberculosis.

**Table2. Major changes in caring for patients with tuberculosis in China during the COVID-19 pandemic**

<b>Category</b>	<b>Major changes</b>
Anti-TB treatment	Provide long-term prescription for TB medications Convert injectable treatments to oral regimens for patients with multidrug-resistant TB Use digital medical technologies for patients' follow-up and clinical assessment
Patients' support	Provide web-based education for both TB and COVID-19 Develop and disseminate paper educational materials on COVID-19 for patients and their accompany Use digital medical technologies and telephone for patients' counselling
Infection prevention and control	Screen all patients and visitors for the symptoms of COVID-19 and fever Ask epidemiological history of COVID-19 for each patient Isolate patients who had symptoms consistent with COVID-19 Minimize patients' unnecessary visits to the hospital (online appointment, remote diagnosis and treatment services) Minimize the number of hospitalizations, set strict indications of hospitalization Set restriction for maximum outpatient visits and visitors to accompany All TB patients should be screened for COVID-19 through an appropriate triage system Strengthen environmental disinfection and ventilation system for TB Use upper-room germicidal ultraviolet (UGA) system in consulting room and wards for TB Reduce the usage of usage of bronchoscopy for TB patients All patients and visitors should wear a surgical mask Medical staff is required to wear particulate respirators, the consciousness of wearing particulate respirators is high